Related Experiment Video
Updated: May 15, 2025
Assessing Endothelial Vasodilator Function with the Endo-PAT 2000
Published on: October 15, 2010
Treatment of endothelial cell dysfunction in atherosclerosis: a new perspective integrating traditional and modern
Luqun Yang1, Xinjian Li1, Lin Ni1
1Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Taiyuan, China.
Insights
Endothelial cell dysfunction (ECD) drives atherosclerosis (AS), a major cause of cardiovascular disease. Emerging biotherapies and gene therapies show promise for treating ECD and AS, though challenges remain.
Area of Science:
- Cardiovascular Research
- Endothelial Cell Biology
- Vascular Medicine
Background:
- Atherosclerosis (AS) is a leading cause of cardiovascular disease, initiated by endothelial cell dysfunction (ECD).
- Endothelial cells are critical for vascular homeostasis, redox balance, and inflammation control.
- ECD is an early indicator and driver of AS progression.
Purpose of the Study:
- To systematically review current and novel treatment strategies for endothelial cell dysfunction (ECD) in atherosclerosis (AS).
- To analyze the mechanisms and efficacy of various therapeutic approaches for improving endothelial function and reversing AS.
- To provide insights for clinical practice and advance cardiovascular disease prevention and treatment.
Main Methods:
- Systematic literature review of treatment strategies for ECD.
- Analysis of mechanisms of action for different therapies.
- Evaluation of therapeutic efficacy and safety data.
Main Results:
- Traditional treatments (lifestyle, pharmacotherapy) improve endothelial function by managing risk factors.
- Novel biotherapies and gene therapies show significant potential for reversing ECD and AS.
- Current treatments face challenges in efficacy, long-term safety, and ethical considerations.
Conclusions:
- ECD is a critical target for AS intervention.
- Biotherapy and gene therapy represent promising avenues for cardiovascular disease treatment.
- Further research is needed to overcome challenges and optimize therapeutic strategies for ECD and AS.
Abstract:
Atherosclerosis (AS), a prime causative factor in cardiovascular disease, originates from endothelial cell dysfunction (ECD). Comprising a vital part of the vascular endothelium, endothelial cells play a crucial role in maintaining vascular homeostasis, optimizing redox balance, and regulating inflammatory responses. More evidence shows that ECD not only serves as an early harbinger of AS but also exhibits a strong association with disease progression. In recent years, the treatment strategies for ECD have been continuously evolving, encompassing interventions ranging from lifestyle modifications to traditional pharmacotherapy aimed at reducing risk factors, which also have demonstrated the ability to improve endothelial cell function. Additionally, novel strategies such as promising biotherapy and gene therapy have drawn attention. These methods have demonstrated enormous potential and promising prospects in improving endothelial function and reversing AS. However, it is essential to remain cognizant that the current treatments still present significant challenges regarding therapeutic efficacy, long-term safety, and ethical issues. This article aims to provide a systematic review of these treatment methods, analyze the mechanisms and efficacy of various therapeutic strategies, with the goal of offering insights and guidance for clinical practice, and further advancing the prevention and treatment of cardiovascular diseases.
Related Concept Videos
01:17Ischemic Heart Disease: Overview
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
01:18Cardiovascular Drugs: Classification based on Therapeutic Indications
01:15Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...